From the Journals

More weight loss with time-restricted eating


 

TOPLINE:

Time-restricted eating (TRE), also known as intermittent fasting, for a daily 8-hour period without calorie counting produced greater weight loss among people with type 2 diabetes and obesity, compared with calorie restriction, while hemoglobin A1c levels dropped with both approaches, compared with no intervention.

METHODOLOGY:

  • Six-month clinical trial of 75 adult participants with type 2 diabetes and obesity, randomly assigned to either 8-hour TRE (noon to 8 p.m. only) without calorie counting, a 25% daily calorie restriction, or control.

TAKEAWAY:

  • The primary outcome, change in body weight at month 6, was –3.56% (P = .004) with TRE vs. –1.78% with calorie restriction (P = .06), compared with controls.
  • The mean calorie deficit over the 6 months was –313 kcal/day with TRE, –197 kcal/day with calorie restriction, and –16 kcal/day for controls.
  • Self-reported adherence to the regimens was 87% of days with 8-hour TRE vs. 68% reporting adherence with calorie goals over the 6 months.
  • A1c levels were reduced significantly by 0.91% in the TRE group and 0.94% in the calorie-restriction group, relative to controls, with no differences between the two intervention groups.
  • No serious adverse events were reported.
  • Hypoglycemia and hyperglycemia occurrences didn’t differ between groups.

IN PRACTICE:

“Our findings ... show that TRE is safe in patients who are using either diet alone or medications to control their [type 2 diabetes]. However, for people using sulfonylureas and/or insulin, adopting a TRE regimen will require medication changes and regular monitoring, particularly in the initial stages of the diet.”

SOURCE:

The study was conducted by Vasiliki Pavlou, MS, RD, of the department of kinesiology and nutrition, University of Illinois at Chicago, and colleagues. It was published online in JAMA Network Open.

LIMITATIONS:

  • Relatively short trial duration.
  • Lack of blinding.
  • A higher proportion in the TRE group were using newer type 2 diabetes medications at baseline.
  • Self-reported dietary intake.

DISCLOSURES:

The study was supported by the University of Illinois at Chicago, and by grants from the National Institutes of Health. Ms. Pavlou reports no relevant financial relationships. Several authors reported relationships with industry. The full list can be found with the original article.

A version of this article first appeared on Medscape.com.

Recommended Reading

New ‘twincretin’ pemvidutide: Another option for obesity
Clinician Reviews
Metformin, weight management to stop type 2 diabetes in kids
Clinician Reviews
Scientists find the ‘on’ switch for energy-burning brown fat
Clinician Reviews
Addressing obesity bias in health care
Clinician Reviews
Taking a new obesity drug and birth control pills? Be careful
Clinician Reviews
Antidepressants ‘don’t blunt’ semaglutide and weight loss
Clinician Reviews
ESG yields significant, sustained weight loss across obesity classes
Clinician Reviews
What predicts successful weight loss maintenance in WeightWatchers?
Clinician Reviews
Bariatric surgery, including sleeve gastrectomy, linked to fracture risk
Clinician Reviews
Higher weight loss on tirzepatide links to seven factors
Clinician Reviews